期刊语言：英语

出版地区：美国

万维提示

1、投稿方式：在线投稿。

2、期刊网址：

https://www.clinical-colorectal-cancer.com/

https://www.journals.elsevier.com/clinical-colorectal-cancer

3、投稿网址：

https://www.editorialmanager.com/CCRC/default.aspx

4、官网邮箱：clcc@elsevier.com（编辑部）

5、期刊刊期：季刊，逢季末月出版。

2022年1月18日星期二

投稿须知【官网信息】

Guide for Authors

Clinical Colorectal Cancer is a peer-reviewed, quarterly journal that publishes original articles describing various aspects of clinical and translational research of gastrointestinal cancers. Clinical Colorectal Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of colorectal, pancreatic, liver, and other gastrointestinal cancers. The main emphasis is on recent scientific developments in all areas related to gastrointestinal cancers. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches

Types of paper

Reviews: Review articles collate, describe, and evaluate prior publications of important clinical subjects, accompanied by critical analysis leading to rational conclusions. These Reviews should contain very little, if any, original data from an author's own study; however, such data can be used to support the overall thesis of the article. We also accept targeted mini-reviews that cover specific topics or therapies.

Mechanics: Reviews articles should contain a short abstract stating the goal of the review, an introduction, discussion, and conclusion. We recommend that Review articles contain 2000-10,000 words, ≤ 7 figures and/or tables, and 50-120 references.

Perspectives: Perspectives are more focused than reviews and seek to review a topic from a particular view or opinion. Perspectives should review a particular field to identify outstanding issues and/or challenges and propose new hypotheses or directions. A Perspective may highlight emerging science, controversial opinions, or issues within the field and seek to address these controversies. They may be accepted from a single individual or a team.

Mechanics: Perspectives should contain a short abstract stating the goal of the review, an introduction, discussion, and conclusion. We recommend that Perspective articles contain 2000-8000 words, ≤ 7 figures and/or tables, and 45-90 references.

Original Studies: Original Studies articles present results of original clinical and/or translational (basic research with clinical applications) research. This article focuses on new data collected by the author(s) during the course of a clinical or preclinical trial, although other studies may be cited for support. The Original Study should contain the following sections: Title Page, Structured Abstract, Introduction, Patients (or Materials) and Methods, Results, Discussion, and Conclusion.

Mechanics: Original Studies should contain a MicroAbstract and a structured abstract with the following sections: Background (or Purpose), Patients (or Materials) and Methods, Results, and Conclusion. Original Studies should also contain a short clinical practice points section after the conclusion of the manuscript. We recommend that Original Studies contain 2000-8000 words, ≤ 7 figures and/or tables, and 30-60 references.

Therapeutic studies:

Clinical study:

Planned studies with a protocol / ethics committee/ registered trial. Please distinguish between 2 fields:

Single arm phase I/II trials

Secondary endpoints from randomized trials (e.g. OoL analyses, 2ndary endpoints, etc.)

Translational research (in parallel to preplanned clinical study): Please distinguish:

Please distinguish:

Preplanned analyses with a hypothesis.

Prognostic / epidemiologic studies: Pre-planned cohorts and pre-defined questions, prospective study.

Biomarker focus ? patient material: Pre-planned with clinical study or with registry.

Biomarker focus ? preclinical: Retrospective analyses of tissue / other biomaterial will consider these types of studies only in exceptional cases. Under ideal circumstance, the pre-clinical biomarker studies are accompanied by biomarker studies incorporated as part of the clinical trial.

……

更多详情：

https://www.elsevier.com/journals/clinical-colorectal-cancer/1533-0028/guide-for-authors